{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:20:11Z","timestamp":1773926411166,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.pupt.2023.102214","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T18:54:51Z","timestamp":1680202491000},"page":"102214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6525-9190","authenticated-orcid":false,"given":"S.","family":"Naehrig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Schulte-Hubbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hafkemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hammermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dumke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Naehrlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2023.102214_bib1","series-title":"Cystic Fibrosis","author":"Hodson and Geddes","year":"2016"},{"key":"10.1016\/j.pupt.2023.102214_bib2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0022-3476(05)82653-8","article-title":"Pulmonary function and clinical course in pwCF with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa","volume":"116","author":"Kerem","year":"1990","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.pupt.2023.102214_bib3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1067\/mpd.2001.112897","article-title":"Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis","volume":"138","author":"Nixon","year":"2001","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.pupt.2023.102214_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.00166412","article-title":"ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry","volume":"43","author":"Kerem","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2023.102214_bib5","article-title":"Lungenerkrankung bei Mukoviszidose: Pseudomonas aeruginosa","volume":"27.09","year":"2022","journal-title":"Version Datum"},{"issue":"Suppl 1","key":"10.1016\/j.pupt.2023.102214_bib6","article-title":"European cystic fibrosis society standards of care: best practice guidelines","volume":"13","author":"Smyth","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"187","key":"10.1016\/j.pupt.2023.102214_bib7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines","volume":"2013","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.pupt.2023.102214_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.pupt.2023.102214_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics"},{"issue":"1","key":"10.1016\/j.pupt.2023.102214_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in pwCF with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.pupt.2023.102214_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/19.6.831","article-title":"Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"19","author":"Jensen","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.pupt.2023.102214_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1592\/phco.31.2.146","article-title":"Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis","volume":"31","author":"Berlana","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.pupt.2023.102214_bib36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jcf.2016.05.001","article-title":"Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis","volume":"15","author":"Flume","year":"2015","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.pupt.2023.102214_bib12","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jcf.2016.09.002","article-title":"Continuous alternating inhaled antibiotic therapy in CF: a single center retrospective analysis","volume":"15","author":"Van de Kerkhove","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102214_bib39","first-page":"S1569","article-title":"ECFSPR Scientific Committee. Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection - a European cystic fibrosis patient registry data analysis","author":"Orenti","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102214_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis pwCF","volume":"2","author":"Lee","year":"2003","journal-title":"J. Cyst. Fibros."},{"issue":"10 Suppl","key":"10.1016\/j.pupt.2023.102214_bib14","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1569-1993(11)60011-8","article-title":"Chronic Pseudomonas aeruginosa infection definition: EuroCareCF working group report","volume":"2011","author":"Pressler","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102214_bib16","author":"UK Cystic Fibrosis"},{"issue":"7","key":"10.1016\/j.pupt.2023.102214_bib32","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/ppul.25942","article-title":"Use of inhaled antibiotics among Danish patients with cystic fibrosis","volume":"57","author":"M\u00f8ller","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.pupt.2023.102214_bib18","author":"The Canadian Cystic Fibrosis Registry Annual Report"},{"key":"10.1016\/j.pupt.2023.102214_bib19","author":"CFF Patient Registry"},{"issue":"9","key":"10.1016\/j.pupt.2023.102214_bib20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ppul.20873","article-title":"Shifting patterns of inhaled antibiotic use in cystic fibrosis","volume":"43","author":"Moskowitz","year":"2008","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.pupt.2023.102214_bib21","series-title":"18th Annual Cystic Fibrosis Conference 2004. Pediatr Pulmonol 2004: Abstract 278","article-title":"A dry powder formulation of colistimethate sodium is safe and well-tolerated in adults and children with CF","author":"Davies","year":"2004"},{"issue":"4","key":"10.1016\/j.pupt.2023.102214_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in pwCF with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2023.102214_bib23","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","author":"Smith","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.pupt.2023.102214_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.pupt.2023.102214_bib25","first-page":"P419","article-title":"A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis","volume":"11","author":"Littlewood","year":"2012","journal-title":"JCF"},{"key":"10.1016\/j.pupt.2023.102214_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.1125","article-title":"et Nahata NC 2001: efficacy and Safety of Aerosolized Tobramycin in Cystic Fibrosis","volume":"32","author":"Pai","year":"2001","journal-title":"Pediatr. Pulmonol."},{"issue":"3","key":"10.1016\/j.pupt.2023.102214_bib27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.amjoto.2019.03.012","article-title":"Vestibulotoxicity in a patient without renal failure after inhaled tobramycin","volume":"40","author":"Kaufman","year":"2019","journal-title":"Am. J. Otolaryngol."},{"key":"10.1016\/j.pupt.2023.102214_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.rmed.2018.03.034","article-title":"Treatment compliance in cystic fibrosis pwCF with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: the FREE study","volume":"138","author":"Blasi","year":"2018","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.pupt.2023.102214_bib29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jcf.2020.08.001","article-title":"Long-term safety study of colistimethate sodium (Colobreathe\u00ae): findings from the UK cystic fibrosis registry","volume":"20","author":"Kaplan","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.pupt.2023.102214_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pec.2008.08.027","article-title":"Adherence to nebulized antibiotics in cystic fibrosis","volume":"2009","author":"Latchford","year":"2009","journal-title":"Patient Educ. Counsel."},{"key":"10.1016\/j.pupt.2023.102214_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2466-11-5","article-title":"Adherence with tobramycin inhaled solution and health care utilization","volume":"11","author":"Briesacher","year":"2011","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.pupt.2023.102214_bib33","first-page":"425","volume":"140","author":"Daniels","year":"2011"},{"issue":"14","key":"10.1016\/j.pupt.2023.102214_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcf.2014.11.005","article-title":"Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of pwCF receiving multiple inhaled antibiotic classes","volume":"2015","author":"Dasenbrook","year":"2015","journal-title":"J. Cyst. Fibros."},{"issue":"10","key":"10.1016\/j.pupt.2023.102214_bib35","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.clinthera.2016.08.014","article-title":"Comparison of inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa lung infection in PwCF with cystic fibrosis: systematic literature review and network meta-analysis","volume":"38","author":"Elborn","year":"2016","journal-title":"Clin. Therapeut."},{"issue":"1","key":"10.1016\/j.pupt.2023.102214_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis pwCF: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J. Cyst. Fibros."},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2023.102214_bib38","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0954-6111(11)70022-1","article-title":"Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?","volume":"105","author":"Lo","year":"2011","journal-title":"Respir. Med."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:31:40Z","timestamp":1761082300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553923000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":38,"alternative-id":["S1094553923000263"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102214","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102214"}}